NuVision Biotherapies
The company manufactures Omnigen, a wound dressing and grafting material derived from amniotic membrane using a patented preservation process called Tereo. These biotherapies are designed to treat ocular surface diseases and injuries by supporting natural healing and recovery. The products are used by ophthalmologists and clinicians in surgical and outpatient settings, often applied via the OmniLenz bespoke contact lens.
Healthtech
Biotechnology
Ophthalmology
Medical Devices
Funding summary
- Total raised
- €7.2M
- Funding rounds
- 3
Investors in NuVision Biotherapies
Investors on record for NuVision Biotherapies. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like NuVision Biotherapies?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors